The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
A Prognostic DNA Methylation Signature for Stage I Non–Small-Cell Lung Cancer
Open accessAbstract
Purpose: Non–small-cell lung cancer (NSCLC) is a tumor in which only small improvements in clinical outcome have been achieved. The issue is critical for stage I patients for whom there are no available biomarkers that indicate which high-risk patients should receive adjuvant chemotherapy. We aimed to find DNA methylation markers that could be helpful in this regard. Patients and Methods: A DNA methylation microarray that analyzes 450,000 CpG sites was used to study tumoral DNA obtained from 444 patients with NSCLC that included 237 stage I tumors. The prognostic DNA methylation markers were validated by a single-methylation pyrosequencing assay in an independent cohort of 143 patients with stage I NSCLC. Results: Unsupervised clustering of the 10,000 most variable DNA methylation sites in the discovery cohort identified patients with high-risk stage I NSCLC who had shorter relapse-free survival (RFS; hazard ratio [HR], 2.35; 95% CI, 1.29 to 4.28; P = .004). The study in the validation cohort of the significant methylated sites from the discovery cohort found that hypermethylation of five genes was significantly associated with shorter RFS in stage I NSCLC: HIST1H4F, PCDHGB6, NPBWR1, ALX1, and HOXA9. A signature based on the number of hypermethylated events distinguished patients with high- and low-risk stage I NSCLC (HR, 3.24; 95% CI, 1.61 to 6.54; P = .001). Conclusion: The DNA methylation signature of NSCLC affects the outcome of stage I patients, and it can be practically determined by user-friendly polymerase chain reaction assays. The analysis of the best DNA methylation biomarkers improved prognostic accuracy beyond standard staging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Cancer Incidence in Five Continents
(1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,501
Cancer Incidence in Five Continents
(1966) · doi:10.1007/978-3-642-85849-9 · Cited by 5,936
Revisions in the International System for Staging Lung Cancer
Mountain, C. F. (1997) · Chest · doi:10.1378/chest.111.6.1710 · Cited by 4,565
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Esteller, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072067 · Cited by 3,662
Self-citationGene Silencing in Cancer in Association with Promoter Hypermethylation
Herman, J. G., & Baylin, S. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023075 · Cited by 3,422
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Self-citationIrizarry, R. A., Ladd-Acosta, C., Wen, B., Wu, Z., Montano, C., Onyango, P., Cui, H., Gabo, K., Rongione, M., Webster, M., et al. (2009) · Nature Genetics · doi:10.1038/ng.298 · Cited by 2,177
Pathology and genetics of tumours of the lung , pleura, thymus and heart
Travis, W. D. (2004) · Cited by 1,955
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., Cormier, Y., Goss, G., Inculet, R., Vallieres, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043623 · Cited by 1,810
High density DNA methylation array with single CpG site resolution
Bibikova, M., Barnes, B., Tsan, C., Ho, V., Klotzle, B., Le, J. M., Delano, D., Zhang, L., Schroth, G. P., Gunderson, K. L., et al. (2011) · Genomics · doi:10.1016/j.ygeno.2011.07.007 · Cited by 1,727
Douillard, J.-Y., Rosell, R., De Lena, M., Carpagnano, F., Ramlau, R., Gonzáles-Larriba, J. L., Grodzki, T., Pereira, J. R., Le Groumellec, A., Lorusso, V., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70804-x · Cited by 1,573
Self-citationIncreased methylation variation in epigenetic domains across cancer types
Hansen, K. D., Timp, W., Bravo, H. C., Sabunciyan, S., Langmead, B., McDonald, O. G., Wen, B., Wu, H., Liu, Y., Diep, D., et al. (2011) · Nature Genetics · doi:10.1038/ng.865 · Cited by 1,045
Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome
Sandoval, J., Heyn, H., Moran, S., Serra-Musach, J., Pujana, M. A., Bibikova, M., & Esteller, M. (2011) · Epigenetics · doi:10.4161/epi.6.6.16196 · Cited by 990
Self-citationStrauss, G. M., Herndon, J. E., Maddaus, M. A., Johnstone, D. W., Johnson, E. A., Harpole, D. H., Gillenwater, H. H., Watson, D. M., Sugarbaker, D. J., Schilsky, R. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.4855 · Cited by 974
Incidence of local recurrence and second primary tumors in resected stage I lung cancer
Martini, N., Bains, M. S., Burt, M. E., Zakowski, M. F., McCormack, P., Rusch, V. W., & Ginsberg, R. J. (1995) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(95)70427-2 · Cited by 973
Juergens, R. A., Wrangle, J., Vendetti, F. P., Murphy, S. C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C. M., Franco, N., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0214 · Cited by 686
Hoffman, P. C., Mauer, A. M., & Vokes, E. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)82038-3 · Cited by 605
Scagliotti, G. V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg059 · Cited by 593
Self-citationDNA Methylation Markers and Early Recurrence in Stage I Lung Cancer
Brock, M. V., Hooker, C. M., Ota-Machida, E., Han, Y., Guo, M., Ames, S., Glöckner, S., Piantadosi, S., Gabrielson, E., Pridham, G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706550 · Cited by 593
Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression
Selamat, S. A., Chung, B. S., Girard, L., Zhang, W., Zhang, Y., Campan, M., Siegmund, K. D., Koss, M. N., Hagen, J. A., Lam, W. L., et al. (2012) · Genome Research · doi:10.1101/gr.132662.111 · Cited by 521
A DNA methylation fingerprint of 1628 human samples
Fernandez, A. F., Assenov, Y., Martin-Subero, J. I., Balint, B., Siebert, R., Taniguchi, H., Yamamoto, H., Hidalgo, M., Tan, A.-C., Galm, O., et al. (2012) · Genome Research · doi:10.1101/gr.119867.110 · Cited by 411
Self-citationArriagada, R., Dunant, A., Pignon, J.-P., Bergman, B., Chabowski, M., Grunenwald, D., Kozlowski, M., Le Péchoux, C., Pirker, R., Pinel, M.-I. S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2272 · Cited by 394
WALLER, D., PEAKE, M., STEPHENS, R., GOWER, N., MILROY, R., PARMAR, M., RUDD, R., SPIRO, S., & ONBEHALFOFALLBLTPARTICIPANTS (2004) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2004.03.041 · Cited by 387
Kratz, J. R., He, J., Van Den Eeden, S. K., Zhu, Z.-H., Gao, W., Pham, P. T., Mulvihill, M. S., Ziaei, F., Zhang, H., Su, B., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61941-7 · Cited by 333
The changing epidemiology of lung cancer in Europe
Janssen-Heijnen, M. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)00230-7 · Cited by 301
Rauch, T., Wang, Z., Zhang, X., Zhong, X., Wu, X., Lau, S. K., Kernstine, K. H., Riggs, A. D., & Pfeifer, G. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701059104 · Cited by 287
Ramalingam, S. S., Maitland, M. L., Frankel, P., Argiris, A. E., Koczywas, M., Gitlitz, B., Thomas, S., Espinoza-Delgado, I., Vokes, E. E., Gandara, D. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9094 · Cited by 273
Identification of 20 genes aberrantly methylated in human breast cancers
Miyamoto, K., Fukutomi, T., Akashi‐Tanaka, S., Hasegawa, T., Asahara, T., Sugimura, T., & Ushijima, T. (2005) · International Journal of Cancer · doi:10.1002/ijc.21054 · Cited by 194
Claus, R., Lucas, D. M., Stilgenbauer, S., Ruppert, A. S., Yu, L., Zucknick, M., Mertens, D., Bühler, A., Oakes, C. C., Larson, R. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.3090 · Cited by 147
Clustering of Gene Hypermethylation Associated With Clinical Risk Groups in Neuroblastoma
Alaminos, M., Dávalos, V., Cheung, N. V., Gerald, W. L., & Esteller, M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh224 · Cited by 129
Self-citationFujisawa, T., Iizasa, T., Saitoh, Y., Sekine, Y., Motohashi, S., Yasukawa, T., Shibuya, K., Hiroshima, K., & Ohwada, H. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2086 · Cited by 124
Discovery and Validation of 3 Novel DNA Methylation Markers of Prostate Cancer Prognosis
Cottrell, S. E., Jung, K., Kristiansen, G., Eltze, E., Semjonow, A., Ittmann, M., Hartmann, A., Stamey, T. A., Haefliger, C., & Weiss, G. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.01.010 · Cited by 97
Genome-wide CpG island methylation analyses in non-small cell lung cancer patients
Heller, G., Babinsky, V. N., Ziegler, B., Weinzierl, M., Noll, C., Altenberger, C., Müllauer, L., Dekan, G., Grin, Y., Láng, G., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs363 · Cited by 82
The relationship between aberrant methylation and survival in non-small-cell lung cancers
Toyooka, S., Suzuki, M., Maruyama, R., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602013 · Cited by 71
Son, J. W., Jeong, K. J., Jean, W.-S., Park, S. Y., Jheon, S., Cho, H. M., Park, C. G., Lee, H. Y., & Kang, J. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.06.021 · Cited by 58
Aberrant DNA Methylation of OLIG1, a Novel Prognostic Factor in Non-Small Cell Lung Cancer
Brena, R. M., Morris, Q., Liyanarachchi, S., Jarjoura, D. G., Davuluri, R. V., Otterson, G. A., Reisman, D., Glaros, S., Rush, L. J., & Plass, C. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040108 · Cited by 56
Nelson, H. H., Marsit, C. J., Christensen, B. C., Houseman, E. A., Kontić, M., Wiemels, J. L., Karagas, M. R., Wrensch, M., Zheng, S., Wiencke, J. K., et al. (2012) · Epigenetics · doi:10.4161/epi.20219 · Cited by 51
Vinci, A. D., Casciano, I., Marasco, E., Banelli, B., Ravetti, G. L., Borzì, L., Brigati, C., Forlani, A., Dorcaratto, A., Allemanni, G., et al. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1070-5 · Cited by 49
Cited by
Moran, S., Arribas, C., & Esteller, M. (2016) · Epigenomics · doi:10.2217/epi.15.114 · Cited by 697
Self-citationBiomarker development in the precision medicine era: lung cancer as a case study
Vargas, A. J., & Harris, C. C. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.56 · Cited by 556
Lung Cancer Staging and Prognosis
Woodard, G. A., Jones, K. D., & Jablons, D. M. (2016) · Cancer Treatment and Research · doi:10.1007/978-3-319-40389-2_3 · Cited by 366
miRNA: A Promising Therapeutic Target in Cancer
Menon, A., Abd-Aziz, N., Khalid, K., Poh, C. L., & Naidu, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911502 · Cited by 357
Li, Y., Ge, D., & Lu, C. (2019) · Epigenetics & Chromatin · doi:10.1186/s13072-019-0316-3 · Cited by 285
Metadata
- Authors
- Sandoval, J., Mendez-Gonzalez, J., Nadal, E., Chen, G., Carmona, F. J., Sayols, S., Moran, S., Heyn, H., Vizoso, M., Gomez, A., Sanchez-Cespedes, M., Assenov, Y., Müller, F., Bock, C., Taron, M., Mora, J., Muscarella, L. A., Liloglou, T., Davies, M., Pollan, M., Pajares, M. J., Torre, W., Montuenga, L. M., Brambilla, E., Field, J. K., Roz, L., Lo Iacono, M., Scagliotti, G. V., Rosell, R., Beer, D. G., & Esteller, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-11-10
- Volume
- 31
- Issue
- 32
- Pages
- 4140-4147
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1997434130
- Cited by
- 278
- References
- 41
- FWCI
- 12.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.